IsoTis also announced that it will host two conference calls on October 17, where investors can ask questions about the special stockholders meeting in German, French, Dutch or English:
Conference call details
Date: October 17, 2007
German / French / English operator
Time: 16:30-17:30 CET
Dial In: 00-41-(0)91-610-5609
Dutch / English operator
Time: 17:30-18:30 CET
Dial In: 00-800-4546-4748
The IsoTis Board of Directors continues to believe unanimously that the interests of IsoTis' stockholders are best served by the acquisition by Integra, and that there are no feasible alternatives for the company and the stockholders. If IsoTis is unable to obtain the vote necessary to approve the proposed transaction, the company believes it will have to seek bankruptcy protection.
IsoTis is an orthobiologics company that develops, manufactures and markets proprietary products for the treatment of musculoskeletal diseases and disorders. IsoTis' current orthobiologics products are bone graft substitutes that promote the regeneration of bone and are used to repair natural, trauma-related and surgically-created defects common in orthopedic procedures, including spinal fusions. IsoTis' current commercial business is highlighted by its Accell line of products, which the company believes represents the next generation in bone graft substitution.
On August 7, 2007 Integra and IsoTis announced that they have reached a
definitive agreement to create a global orthobiologics leader. The
combination would create a comprehensive orthobiologics portfolio, one of
|SOURCE IsoTis Inc|
Copyright©2007 PR Newswire.
All rights reserved